Understanding the Risks Associated with Weight-Loss Medications: Ozempic and Wegovy

You may have come across the enticing commercials or heard about the prescription drugs Ozempic and Wegovy, which are utilized for weight loss or to manage Type 2 diabetes. You might even be contemplating discussing these medications with your physician to explore the possibility of prescribing them for you.

In the United States, where approximately 42% of adults grapple with obesity, the demand for these drugs is surging, resulting in a supply shortage. Both Wegovy and Ozempic have found a place on the U.S. Food and Drug Administration's list of drugs in short supply. To address this issue, Novo Nordisk, the manufacturer, has expressed its commitment to boosting manufacturing capacity to ensure a more robust supply of Wegovy. However, at least until September, Americans might encounter difficulties filling prescriptions for dosages ranging from 0.25 mg to 1 mg.

Despite their popularity, it's crucial to take various factors into consideration before deciding to use these drugs. A warning from the American Society of Anesthesiologists in late June highlights the surgery risks associated with the intake of these medications. Additionally, in Europe, ongoing scrutiny is being directed toward Wegovy, Ozempic, and another weight-loss drug called Saxenda, to investigate whether they may heighten the risk of suicidal thoughts and self-injury.

To gain deeper insights into these matters, the Free Press sought counsel from medical experts: Dr. Suki Singh, the medical director of weight management and obesity medicine at Henry Ford Health System, and Jodie Emerson, a certified nurse anesthetist and president-elect of the Michigan Association of Nurse Anesthetists.

Unveiling the Mechanisms of Wegovy and Ozempic Both Wegovy and Ozempic share the same active ingredient, semaglutide, and are administered through weekly injections. Wegovy, however, stands out as a stronger and more concentrated version of semaglutide than Ozempic. The efficacy of these drugs lies in their ability to mimic a hormone called glucagon-like peptide-1 found in the human body. This mimicry influences appetite regulation, enhances insulin production, slows digestion, and promotes a prolonged feeling of fullness.

Eligibility and FDA Approvals The FDA has greenlit Wegovy for weight loss in individuals with a body mass index (BMI) of 27 or higher, coupled with an underlying health condition that can be improved through weight loss. It has also been approved for use in people with a BMI of 30 or higher without any complicating medical conditions.

There is a category of patients with a BMI of 30 or above who lack secondary conditions but can still be prescribed these medications. Taking preventative measures early on for individuals with conditions like hyperlipidemia, which poses a higher risk for heart disease, can garner insurance companies' support for this proactive approach.

Alternatives to Consider Apart from Wegovy, several other weight-loss options exist, including Trulicity, Mounjaro, phentermine, Qsymia, and Contrave. Each patient's unique circumstances necessitate a tailored treatment plan, with some responding well to oral medications, while others find success with injections.

Exploring Costs and Insurance Coverage Costs can vary significantly depending on insurance coverage. While some medications like phentermine can cost around $15 to $20 with a coupon from goodrx.com, Qsymia and Contrave are priced between $150 to $200 per month. Wegovy and Ozempic, being higher-cost drugs, may range from $1,000 to $1,300 per month. Insurance companies may require a prior authorization for these medications based on BMI levels and the presence of specific conditions.

Long-Term Maintenance and Importance of Weight Loss As obesity is a chronic and multifactorial condition, the duration of medication usage may differ for each patient. In postmenopausal women, for instance, muscle mass decline during menopause can contribute to weight gain. Hence, a holistic approach involving lifestyle changes, strength training, and nutrition is vital for long-term weight management.

Surgery Risks and Precautions One crucial aspect to consider is the potential risk associated with surgery for individuals taking Wegovy and Ozempic. These drugs slow down digestion, which may lead to nausea and vomiting under anesthesia. Hence, the FDA advises discontinuing their use for at least a week before elective surgery. In cases where stopping the medication is not feasible, an ultrasound to check stomach emptiness is recommended.

Side Effects and Contraindications As with any medication, Wegovy and Ozempic have potential side effects, including nausea, diarrhea, vomiting, and hypoglycemia. Individuals with an allergy to semaglutide, a history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should avoid taking these drugs. The FDA also highlights the risk of thyroid tumors, pancreatitis, gallstones, increased heart rate, low blood sugar, kidney injury, vision changes, and a possibility of suicidal behavior and self-harm while using these medications.

In Conclusion Before embarking on a weight-loss journey with Wegovy or Ozempic, it is essential to have an open dialogue with your healthcare provider, discussing your specific goals and risk factors. Although these drugs can aid in weight loss, they may not be the sole solution for long-term success. Embracing a comprehensive approach involving medical guidance, lifestyle changes, and understanding one's body will pave the way for effective obesity treatment, just like other chronic medical conditions. Ultimately, prioritizing health and safety during this journey remains paramount.